Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
NCT06224673Phase 2Recruiting
- Sponsor
- Laura Huppert
- Start
- Jun 2026
- Primary completion
- Nov 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of anvatabart opadotin in breast cancer, sponsored by Laura Huppert. Started Jun 2026; status: recruiting.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06224673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224673.